Skip to main content

Table 1 Association between PEG10 expression and clinical characteristics in 147 hepatocellular carcinoma patients

From: miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma

 

PEG10 (+)

PEG10 (−)

P value

N = 83

N = 64

Age (mean)

62.95

62.31

0.662

Gender (M)

58 (69.9 %)

46 (71.9 %)

0.792

Tumor size (cm)

  

0.231

 <2

17 (20.5 %)

7 (10.9 %)

 

 2–5

39 (47.0 %)

30 (46.9 %)

 

 >5

27 (32.5 %)

27 (42.2 %)

 

Vascular invasion

32 (38.6 %)

25 (39.1 %)

0.950

Liver cirrhosis

55 (66.3 %)

42 (65.6 %)

0.935

AJCC T-stage

  

0.144

 I

49 (59.0 %)

36 (56.3 %)

 

 II

17 (20.5 %)

11 (17.2 %)

 

 III

16 (19.3 %)

11 (17.2 %)

 

 IV

1 (1.2 %)

6 (9.4 %)

 

BCLC stage

  

0.159

 0

9 (10.8 %)

2 (3.1 %)

 

 A

44 (53.0 %)

34 (53.1 %)

 

 B

26 (31.3 %)

27 (42.2 %)

 

 C

4 (4.8 %)

1 (1.6 %)

 

Okuda stage

  

0.050

 I

79 (95.2 %)

55 (85.9 %)

 

 II

4 (4.8 %)

9 (14.1 %)

 

Etiology

  

0.173

 Non-viral

11(13.3 %)

15 (23.8 %)

 

 HBV

40 (48.2 %)

31 (48.4 %)

 

 HCV

28 (33.7 %)

13 (20.3 %)

 

 Both

4 (4.8 %)

5 (7.8 %)

 

Histological grade

  

0.001

 Well

6 (7.2 %)

19 (29.7 %)

 

 Moderate

61 (73.5 %)

32 (50 %)

 

 Poor

16 (19.3 %)

13 (20.3 %)

 

Recurrence (>2 year)

12 (14.5 %)

4 (6.3 %)

0.113

AFP (>500 ng/ml)

17 (30.1 %)

5 (15.6 %)

0.055

  1. AJCC American Joint Committee on Cancer, BCLC Barcelona Clinic Liver Cancer, HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us